![](https://news.europawire.eu/wp-content/uploads/2021/01/Sanofi-gains-full-global-rights-to-a-promising-antibody-for-inflammatory-disorders-with-the-acquisition-of-Kymab-144x144.jpg)
(PRESS RELEASE) PARIS/ CAMBRIDGE, 11-Jan-2021 — /EuropaWire/ — French multinational pharmaceutical company Sanofi to acquire Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics. The agreement includes an upfront payment … Read the full press release